Northern Trust Increased Holdings in Collegium Pharmaceutical in Q4

Summary

Northern Trust increased its stake in Collegium Pharmaceutical (NASDAQ: COLL) during the fourth quarter by 5.6%, adding 20,490 shares for a total of 385,157 shares, valued at $11,035,000. Other institutional investors also adjusted their holdings. Collegium’s stock opened at $30.23, with a market cap of $971.35 million. The company reported a net profit margin of 14.78% and a year-over-year revenue growth of 22.7%. Analyst ratings are mixed, with an average target price of $43.80.Market Beat

Impact Analysis

The increase in Northern Trust’s holdings in Collegium Pharmaceutical indicates strong institutional interest and confidence in the company’s future prospects, reflected in their financial performance – notably a 22.7% year-over-year revenue growthMarket Beat. This corporate-level event can lead to positive investor sentiment and potential upward pressure on the stock price, especially given the mixed analyst ratings but a relatively high average target price of $43.80Market Beat. First-order effects include immediate investor reactions to the news, potentially increasing trading volume and stock price volatility. Second-order effects could involve other institutional investors reconsidering their positions in Collegium, influenced by Northern Trust’s actions. For investors, opportunities may lie in buying the stock if bullish on its future prospects or considering options strategies to capitalize on potential volatility.